Please login to the form below

Not currently logged in
Email:
Password:

Belsomra

This page shows the latest Belsomra news and features for those working in and with pharma, biotech and healthcare.

Merck gets Alzheimer’s label claim for insomnia drug Belsomra

Merck gets Alzheimer’s label claim for insomnia drug Belsomra

Critically, unlike some other insomnia drugs like zolpidem, Belsomra doesn’t seem to lead to a significant increase in confusion and falls in people who are cognitively impaired. ... Peak sales of Belsomra are expected to reach around $500m, with the

Latest news

  • Relief as study finds no cardiovascular risk with Januvia Relief as study finds no cardiovascular risk with Januvia

    Meanwhile, first-in-class insomnia therapy Belsomra (suvorexant) and new antibiotic Zerbaxa (ceftolozane/tazobactam) also got off to a good start, according to chief executive Kenneth Frazier.

  • FDA approves Merck’s insomnia drug FDA approves Merck’s insomnia drug

    Belsomra is first orexin receptor antagonist available in US. People with the sleep disorder insomnia now have access to a new treatment option after the FDA approved Merck &Co's Belsomra. ... To cover the varying severity of the disorder, Belsomra is

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics